In Significant Reversal, Prostate Drug Met Primary Goal After All
Summary
In Significant Reversal, Prostate Drug Met Primary Goal After All Xconomy San Diego — After getting something worse than a lump of coal for Christmas last year, Sophiris Bio got an early present for the 2015 holidays— its experimental prostrate drug met the primary goal of a late-stage study.Last December, shares of Sophiris, based in San Diego and Vancouver, BC, plunged more than 80 percent after the company reported interim results, saying the experimental drug failed to meet a pre-defined threshold of efficacy after three months.Rather, the interim results were intended to serve as a snapshot of how well the clinical trial was meeting a pre-defined efficacy threshold after three months, as determined by an independent data monitoring committee.To complete the trial, Sophiris would need to raise additional capital or find a big pharma partner, Woods said.“The analysis showed us a good [almost] 8 point improvement [using the International Prostate Symptom Score] that was maintained through the rest of the study,” Hulme said.